logo-loader
viewVerona Pharma

Verona Pharma's COPD drug 'has potential to significantly benefit patients' - Kathy Rickard

Proactive London's Andrew Scott sat down with Verona Pharma PLC's (LON:VRP) chief medical officer Kathy Rickard.

Rickard recaps on the recent positive top-line Phase 2b results the firm reported for its COPD drug ensifentrine  and discusses why she believes it has the potential to change patients' lives.

She says they're now looking forward to their planned meeting with the U.S. FDA which is due to take place in the second quarter.

Quick facts: Verona Pharma

Price: 42.5 GBX

AIM:VRP
Market: AIM
Market Cap: £45.14 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Verona Pharma named herein, including the promotion by the Company of Verona Pharma in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Verona Pharma has compound with 'massive potential to impact lives of COPD...

Verona Pharma PLC (LON:VRP) chairman David Ebsworth tells Proactive London's Andrew Scott the company's made 'massive progress' in the last few years. ''When we started it was really three or four people, we didn't have a  lot of money, we had early data and over the last five years...

on 2/12/19

2 min read